top of page
Browse by category
Search
Response Pharmaceuticals reveals positive results of RDX-002 in post-GLP-1 management
Response Pharmaceuticals has announced positive top-line results from its double-blind, placebo-controlled Phase 2 clinical trial...
Response Pharmaceuticals completion enrolment of study evaluating RDX-002 post-GLP-1 weight rebound
Response Pharmaceuticals has completed enrolment in a Phase 2 trial evaluating the company’s drug candidate, RDX-002, for post-GLP-1...
Browse by tag
bottom of page